One association submitted a request for access to information addressed to the Ministry of Health, Social Services and Equality to know the sales of biosimilar medicines since 2016.
The Administration provided the information, but the applicant found it insufficient.
When the complaint was filed, the Council of Transparency and Good Government considered it, since it understood that it had not been provided with the information actually required, which included aggregated information on molecules of the biological medicine with respect to the biosimilar in the scope of pharmacies and hospitals at the national level and of CC.AA.
